In a closely watched move, the US Food and Drug Administration late last week released draft guidelines for labeling that should appear on biosimilars. And the directive is likely to give a lift to generic drug makers as they battle their brand-name rivals in this nascent but important market.
The battle over labeling is significant because this information is used by physicians to determine which medicine — the original biologic or the newer biosimilar — to prescribe to patients.
Read Full Article »